Stabilitech, founded in 2002 by Dr. Jeff Drew, is a privately-owned enterprise based in the London Bioscience Innovation Centre, dedicated to stabilizing sensitive biological molecules, including vaccines and biopharmaceuticals. The company's mission revolves around enhancing the stability of these critical components through proprietary formulation technology. This innovative approach ensures the long-term stability of various thermally sensitive viruses, vaccines, and biopharmaceuticals. Notably, the compositions consist of chemical ingredients already approved for clinical use, either as injectables or listed as Generally Regarded As Safe (GRAS). Stabilitech's strategic focus is on commercializing its technology through partnerships with major pharmaceutical and biotechnology firms, as well as global health organizations. In August 2011, the company secured a significant $3.50M Series C investment.
General Information
BounceWatch is an independent company data service, not affiliated with Stabilitech. To contact Stabilitech, visit stabilitech.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Stabilitech compare?
A PDF of Stabilitech and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Stabilitech soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Stabilitech on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
About Stabilitech
Business keywords: biopharmaceuticals, vaccines, stabilization technology, thermally sensitive viruses, formulation technology, biological molecules, drug stability, pharmaceutical partnerships, global health organizations
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series C | $3.50M | - |
|
06 Aug 2011 |
| Debt Financing | £2.20M | - |
|
13 May 2011 |
| Venture Round | £3.30M | - |
|
12 Mar 2009 |
Stabilitech Alternatives & Competitors
View All AlternativesIntensive Vitamin C Treatment to Diminish Wrinkles
Supply Vaccines to Eliminate Human Diseases
We're a growth-oriented biopharmaceutical company improving patient lives by developing and commerci...
FAQ About Stabilitech
Source: BounceWatch company record for Stabilitech, https://www.bouncewatch.com/company/stabilitech, updated 26 December 2024. When citing, please name BounceWatch and link this page.